Key result
Accurate HCM phenotyping identifies distinct prognostic groups to guide sudden cardiac death prevention.
Accurate clinical phenotyping of hypertrophic cardiomyopathy identifies patient subgroups with distinct natural history and prognosis, which is essential for sudden cardiac death risk stratification.
Answers are grounded in this paper and cite their sources.
May refine SCD risk stratification in HCM; leaves open prospective validation of phenotyping algorithms.
Hypertrophic cardiomyopathy is the most common inherited cardiomyopathy and is defined by the presence of left ventricular hypertrophy 15 mm or greater in the absence of any other identifiable cause. Beyond this definition, clinical phenotype is heterogeneous, and associated clinical manifestations occur in varying proportions of patients, including left ventricular outflow tract obstruction, systolic anterior motion of the mitral valve with associated mitral regurgitation, ventricular arrhythmias, and sudden cardiac death. Accurate clinical phenotyping allows the identification of groups with distinct natural history and prognosis, with risk stratification being crucial for prevention of sudden cardiac death.
No takes yet. Share an insight, caveat, or question.
Geenty et al. (2026) conducted a review in Hypertrophic cardiomyopathy. Clinical phenotyping and risk stratification was evaluated on Prevention of sudden cardiac death. Accurate clinical phenotyping of hypertrophic cardiomyopathy (LVH ≥15 mm) identifies groups with distinct prognosis to guide risk stratification for sudden cardiac death prevention.
Synapse has enriched 10 related papers. Consider them for comparative context: